These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27659159)

  • 21. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
    Tsong Y; Yang H
    J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
    [No Abstract]   [Full Text] [Related]  

  • 22. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples.
    Nowatzke W; Woolf E
    AAPS J; 2007 Apr; 9(2):E117-22. PubMed ID: 17614353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.
    Lennernäs H
    Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
    Newby D; Freitas AA; Ghafourian T
    Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.
    Sjögren E; Abrahamsson B; Augustijns P; Becker D; Bolger MB; Brewster M; Brouwers J; Flanagan T; Harwood M; Heinen C; Holm R; Juretschke HP; Kubbinga M; Lindahl A; Lukacova V; Münster U; Neuhoff S; Nguyen MA; Peer Av; Reppas C; Hodjegan AR; Tannergren C; Weitschies W; Wilson C; Zane P; Lennernäs H; Langguth P
    Eur J Pharm Sci; 2014 Jun; 57():99-151. PubMed ID: 24637348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Biopharmaceutics Classification System-based biowaivers.
    Cook JA; Davit BM; Polli JE
    Mol Pharm; 2010 Oct; 7(5):1539-44. PubMed ID: 20735084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.
    Zane P; Gieschen H; Kersten E; Mathias N; Ollier C; Johansson P; Van den Bergh A; Van Hemelryck S; Reichel A; Rotgeri A; Schäfer K; Müllertz A; Langguth P
    Eur J Pharm Biopharm; 2019 Sep; 142():222-231. PubMed ID: 31233862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
    Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
    J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps?
    Flanagan T; Van Peer A; Lindahl A
    Eur J Pharm Sci; 2016 Aug; 91():84-90. PubMed ID: 27283487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
    Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
    AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A science based approach to topical drug classification system (TCS).
    Shah VP; Yacobi A; Rădulescu FŞ; Miron DS; Lane ME
    Int J Pharm; 2015 Aug; 491(1-2):21-5. PubMed ID: 26070249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.